Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

12.57 0.56

Overview

Share price change

24h

Current

Min

12.01

Max

12.61

Key metrics

By Trading Economics

Income

-8.9M

-8M

Sales

3.7M

139M

P/E

Sector Avg

125.6

57.371

Profit margin

-5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+15.04% upside

Market Stats

By TradingEconomics

Market Cap

271M

2.2B

Previous open

12.01

Previous close

12.57

News Sentiment

By Acuity

100%

0%

329 / 340 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 sie 2026, 23:51 UTC

News

Enova International's subsidiary issued $300.89 million in notes, contributing to positive sentiment. The stock is higher in after-market trading, despite recent volatility.

21 sie 2026, 23:46 UTC

News

Home Depot expands roles for three executives, awarding $500,000 in stock grants. Shares were roughly flat during after-market hours following the announcement.

21 sie 2026, 23:41 UTC

News
ETF Constituents

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading, bolstered by gains from UnitedHealth Group and Merck, despite broader market declines.

21 sie 2026, 23:36 UTC

News

Coty Inc reported a fourth-quarter revenue beat but issued weak guidance, resulting in shares trading lower in after-market hours.

21 sie 2026, 23:31 UTC

Correlated Moves
News

Ethereum's price reached $2,371 today, driven by anticipation of Pepeto's Binance listing and Bitcoin's rally past $79,000, boosting market sentiment.

21 sie 2026, 23:26 UTC

Correlated Moves
News

Citigroup Inc shares are lower during after-market hours, reflecting a slight decline amid broader market trends influenced by geopolitical tensions and bargain hunting.

21 sie 2026, 23:21 UTC

Correlated Moves
News
Social Media

Coinbase Global Inc is rising in after-market trading, supported by Bitcoin's significant gain. The company also launched a feature for immediate token access.

21 sie 2026, 23:06 UTC

News

Verizon Communications is deploying resources in response to a potential tropical storm in Hawaii, contributing to lower shares after Friday's close.

21 sie 2026, 23:06 UTC

Correlated Moves
News

KKR & Co Inc reported a net asset value of $8.49 billion as of July 31, contributing to positive sentiment in after-market trading.

21 sie 2026, 23:01 UTC

Social Media
News

Applied Optoelectronics Inc. plans to sell up to $600 million in shares, contributing to a decline in after-market trading amid dilution concerns.

21 sie 2026, 23:01 UTC

News

Hess Midstream LP shares are advancing in after-market trading following a dividend increase and improved free cash flow, despite lower EBITDA and net income.

21 sie 2026, 23:01 UTC

News

Texas Pacific Land Corp shares are higher in after-hours trading, with a market capitalization of $26.49 billion reflecting strong long-term performance.

21 sie 2026, 23:01 UTC

News
Social Media

Sigma Lithium Corp resumes full operations under a new agreement in Brazil, targeting 240,000 tonnes of lithium oxide concentrate. Shares are advancing in after-market trading.

21 sie 2026, 23:01 UTC

News

Spectrum Brands Holdings Inc shares are higher in after-market trading. The company expects low-single-digit revenue growth for fiscal year 2026 amid ongoing cost pressures.

21 sie 2026, 22:01 UTC

News

Cytek Biosciences shares are lower in after-market hours following a jury's $56 million damages award to Beckman Coulter for patent infringement.

21 sie 2026, 20:07 UTC

News
Social Media

Microsoft shares are higher, supported by bullish options activity and a reaffirmed AAA rating from Moody's. The company is part of a $615 billion AI investment group.

21 sie 2026, 20:07 UTC

Social Media
News

Palantir Technologies shares are higher today amid increased options trading and positive sentiment, with Deutsche Bank reiterating a $200 price target.

21 sie 2026, 20:07 UTC

News

Aflac shares are lower today as Japan Post sold 12,700 shares, contributing to negative sentiment amid broader market declines since Thursday's close.

21 sie 2026, 20:07 UTC

News

United Parcel Service shares are trading lower as Zacks cuts Q3 EPS estimate to $1.60. Susquehanna raises target price to $120, maintaining a neutral rating.

21 sie 2026, 20:07 UTC

News

Barclays maintains an Overweight rating on Hims & Hers Health, lowering its price target to $35. Shares are trading higher amid positive market sentiment.

21 sie 2026, 20:07 UTC

News
Correlated Moves

The USD/SEK is trading lower today, continuing a decline since Thursday's close. Earlier in the session, the dollar rebounded from a session low.

21 sie 2026, 20:06 UTC

News

Nu Holdings is higher today, buoyed by a rise in Bitcoin prices following the U.S. Treasury's announcement to double long-dated bond buybacks.

21 sie 2026, 20:06 UTC

News
Correlated Moves

Gold prices are rising, reaching a near three-month high, driven by U.S. Treasury bond buybacks and President Trump's shift in Iran policy.

21 sie 2026, 20:06 UTC

Correlated Moves
News

First Western Financial promotes Brian Weldon to Regional President and Bryce Parietti and Rob Miles to Market Presidents, with shares trading higher today.

21 sie 2026, 20:06 UTC

News

Liquidity Services shares are higher after announcing CEO Bill Angrick's presentation at the Midwest IDEAS Investor Conference on August 26, 2026, in Chicago.

21 sie 2026, 20:06 UTC

News

Palo Alto Networks shares are higher following multiple analyst price target increases, including Cantor Fitzgerald's raise to $425 from $340.

21 sie 2026, 20:06 UTC

News

Citizens Inc shares are lower today, continuing a decline since Thursday amid broader market downturns. The stock remains below its 20-day moving average.

21 sie 2026, 20:06 UTC

News
Social Media

Stoke Therapeutics shares rise following analyst reinstatement with Overweight rating and $40 price target, amid positive sentiment for zorevunersen’s phase III EMPEROR trial.

21 sie 2026, 20:06 UTC

News

T Rowe Price shares are lower as the company pursues its acquisition of F/M Investments, which manages over $10 billion in ETF assets.

21 sie 2026, 20:06 UTC

News

Salesforce Inc is higher as investor interest grows ahead of its August 26 earnings report, with a revenue target of $11.3 billion for Q2.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

15.04% upside

12 Months Forecast

Average 14.53 USD  15.04%

High 16 USD

Low 13.6 USD

Based on 3 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat